☰

Jessica A. Sorrentino, Ph.D. - Publications

Affiliations: 
2013 Toxicology University of North Carolina, Chapel Hill, Chapel Hill, NC 
Area:
Toxicology, Genetics
Tree Info Grants Similar researchers PubMed Report error

33 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Lai AY, Sorrentino JA, Dragnev KH, Weiss JM, Owonikoko TK, Rytlewski JA, Hood J, Yang Z, Malik RK, Strum JC, Roberts PJ. CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy. Journal For Immunotherapy of Cancer. 8. PMID 33004541 DOI: 10.1136/jitc-2020-000847  0.316
2020 Andreano KJ, Wardell SE, Baker JG, Desautels TK, Baldi R, Chao CA, Heetderks KA, Bae Y, Xiong R, Tonetti DA, Gutgesell LM, Zhao J, Sorrentino JA, Thompson DA, Bisi JE, et al. G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer. Breast Cancer Research and Treatment. PMID 32130619 DOI: 10.1007/S10549-020-05575-9  0.347
2020 Bulat I, Maglakelidze M, Murias C, Krastev B, Baird RD, Wardley AM, Roylance R, Crijanovschi A, Gogiladze M, Pritchett Y, McCullough A, Li C, Sorrentino JA, Malik R, Beelen AP. Abstract P1-19-17: Dose escalation and expansion study of lerociclib (G1T38), an oral CDK4/6 inhibitor, dosed with no drug holiday in combination with fulvestrant in patients with HR+/HER2- advanced breast cancer Cancer Research. DOI: 10.1158/1538-7445.Sabcs19-P1-19-17  0.343
2019 Weiss JM, Csoszi T, Maglakelidze M, Hoyer RJ, Beck JT, Gomez MD, Lowczak A, Aljumaily R, Lima CMR, Boccia RV, Hanna W, Nikolinakos P, Chiu VK, Owonikoko TK, Schuster SR, ... ... Sorrentino JA, et al. Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small cell lung cancer receiving 1st-line chemotherapy: a Phase 1b/randomized Phase 2 trial. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 31504118 DOI: 10.1093/Annonc/Mdz278  0.43
2019 Liu JY, Souroullas GP, Diekman BO, Krishnamurthy J, Hall BM, Sorrentino JA, Parker JS, Sessions GA, Gudkov AV, Sharpless NE. Cells exhibiting strong promoter activation in vivo display features of senescence. Proceedings of the National Academy of Sciences of the United States of America. PMID 30683717 DOI: 10.1073/Pnas.1818313116  0.55
2019 O'Shaughnessy J, Wright G, Thummala A, Danso M, Popovic L, Pluard T, Cheung E, Han H, Daniel B, Vojnovic Z, Vasev N, Ling M, Richards D, Wilks S, Milenkovic D, ... Sorrentino J, et al. Abstract PD1-01: Trilaciclib (T), a CDK4/6 inhibitor, dosed with gemcitabine (G), carboplatin (C) in metastatic triple negative breast cancer (mTNBC) patients: Preliminary phase 2 results Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-Pd1-01  0.389
2019 Dai B, Freed DM, Sorrentino JA, Augustine JJ, Hughes TG, Kang Y, Roberts PJ, Fleming JB, Kim MP. Abstract 4732: CDK4/6 inhibition with lerociclib (G1T38) enhances response to PI3K or ERK inhibitors in high-throughput, ex vivo pancreatic PDX screens Cancer Research. 79: 4732-4732. DOI: 10.1158/1538-7445.Am2019-4732  0.402
2019 Berz D, Spira A, Gadgeel S, Anderson I, Goldman J, Thompson J, Foster T, Pritchett Y, Cisneros C, Li C, Sorrentino J, Malik R, Beelen A. Lerociclib (G1T38), an oral CDK4/6 inhibitor, dosed continuously in combination with osimertinib for EGFRmut non-small cell lung cancer: Initial phase Ib results Annals of Oncology. 30: v631. DOI: 10.1093/Annonc/Mdz260.059  0.352
2019 Dees E, Aftimos P, van Oordt H, De Vries E, Neven P, Pegram M, Iqbal R, Boers J, Xiao J, Sipes C, Li C, Sorrentino J, Malik R, Beelen A, Menke-van der C. Dose-escalation study of G1T48, an oral selective estrogen receptor degrader (SERD), in postmenopausal women with ER+/HER2- locally advanced or metastatic breast cancer (ABC) Annals of Oncology. 30: v121-v122. DOI: 10.1093/Annonc/Mdz242.035  0.326
2018 Sorrentino JA, Lai A, Weiss JM, Dragnev KH, Owonikoko TK, Adler S, Antal JM, Malik RK, Roberts PJ. Trilaciclib (trila) preserves and enhances immune system function in extensive-stage small cell lung cancer (ES-SCLC) patients receiving first-line chemotherapy. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: viii598. PMID 32137593 DOI: 10.1093/Annonc/Mdy298.007  0.323
2018 Bulat I, Maglakelidze M, Murias C, Kurteva GP, Roylance R, Gogiladze M, Crijanovschi A, McCullough A, Shearin E, Sorrentino J, Sipes C, Yang Z, Cai Y, Malik RK, Beelen AP. G1T38, an oral CDK4/6 inhibitor, dosed continuously in combination with fulvestrant for HR+ breast cancer: Preliminary phase 1b results. Journal of Clinical Oncology. 36: 1061-1061. DOI: 10.1200/Jco.2018.36.15_Suppl.1061  0.351
2018 Lai AY, Sorrentino JA, Strum JC, Roberts PJ. Abstract 1752: Transient exposure of trilaciclib, a CDK4/6 inhibitor, modulates gene expression in tumor immune infiltrates to promote a pro-inflammatory tumor microenvironment Cancer Research. 78: 1752-1752. DOI: 10.1158/1538-7445.Am2018-1752  0.422
2018 Sorrentino JA, Freed DM, Bisi JE, Strum JC, Roberts PJ. Abstract 1522: The CDK4/6 inhibitor G1T38 enhances response to targeted therapies in preclinical models of non-small cell lung cancer Cancer Research. 78: 1522-1522. DOI: 10.1158/1538-7445.Am2018-1522  0.395
2018 Roberts P, Lai A, Sorrentino J, Malik R. Trilaciclib (G1T28), a CDK4/6 inhibitor, enhances the efficacy of combination chemotherapy and immune checkpoint inhibitor treatment in preclinical models Annals of Oncology. 29: iii4. DOI: 10.1093/Annonc/Mdy046.013  0.346
2017 Deng J, Wang ES, Jenkins RW, Li S, Dries R, Yates K, Chhabra S, Huang W, Liu H, Aref AR, Ivanova E, Paweletz CP, Bowden M, Zhou CW, Herter-Sprie GS, ... Sorrentino JA, et al. CDK4/6 Inhibition Augments Anti-Tumor Immunity by Enhancing T Cell Activation. Cancer Discovery. PMID 29101163 DOI: 10.1158/2159-8290.Cd-17-0915  0.558
2017 He S, Roberts PJ, Sorrentino JA, Bisi JE, Storrie-White H, Tiessen RG, Makhuli KM, Wargin WA, Tadema H, van Hoogdalem EJ, Strum JC, Malik R, Sharpless NE. Transient CDK4/6 inhibition protects hematopoietic stem cells from chemotherapy-induced exhaustion. Science Translational Medicine. 9. PMID 28446688 DOI: 10.1126/Scitranslmed.Aal3986  0.677
2017 Bisi JE, Sorrentino JA, Jordan JL, Darr DD, Roberts PJ, Tavares FX, Strum JC. Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors. Oncotarget. PMID 28418845 DOI: 10.18632/Oncotarget.16216  0.443
2017 Wardell SE, Yllanes AP, Baker JG, Baldi RM, Krebs TK, Sorrentino J, Bisi J, Strum J, Norris JD. Abstract 5641: Effects of G1T48, a novel orally bioavailable selective estrogen receptor degrader (SERD), and the CDK4/6 inhibitor, G1T38, on tumor growth in animal models of endocrine resistant breast cancer Cancer Research. 77: 5641-5641. DOI: 10.1158/1538-7445.Am2017-5641  0.396
2017 Sorrentino JA, Lai AY, Strum JC, Roberts PJ. Abstract 5628: Trilaciclib (G1T28), a CDK4/6 inhibitor, enhances the efficacy of combination chemotherapy and immune checkpoint inhibitor treatment in preclinical models Immunology. 77: 5628-5628. DOI: 10.1158/1538-7445.Am2017-5628  0.348
2017 Guijarro I, Poteete A, Ferrarotto R, Denning W, Hamdi H, Roberts P, Malik R, Bisi J, Sorrentino J, Strum J, Roarty E, Heymach J. P2.03a-048 The CDK4/6 Inhibitor G1T28 Protects Immune Cells from Cisplatin-Induced Toxicity in vivo and Inhibits SCLC Tumor Growth Journal of Thoracic Oncology. 12: S918. DOI: 10.1016/J.Jtho.2016.11.1258  0.372
2016 Bisi JE, Sorrentino JA, Roberts PJ, Tavares FX, Strum JC. Preclinical Characterization of G1T28: A Novel CDK4/6 Inhibitor for Reduction of Chemotherapy-induced Myelosuppression. Molecular Cancer Therapeutics. PMID 26826116 DOI: 10.1158/1535-7163.Mct-15-0775  0.436
2016 Guijarro I, Denning W, Ferrarotto R, Poteete A, Giri U, Bisi JE, Sorrentino JA, Roberts PJ, Strum JC, Malik RK, Roarty E, Heymach J. The CDK4/6 inhibitor G1T28 to protect immune cells and fibroblasts from chemotherapy and radiation-induced toxicity in vitro and to maintain efficacy of chemotherapy in SCLC Rb-deficient cells. Journal of Clinical Oncology. 34: e20099-e20099. DOI: 10.1200/Jco.2016.34.15_Suppl.E20099  0.401
2016 Sorrentino JA, Bisi JE, Roberts PJ, Strum JC. Abstract 2824: G1T38, a novel, oral, potent and selective CDK4/6 inhibitor for the treatment of Rb competent tumors Cancer Research. 76: 2824-2824. DOI: 10.1158/1538-7445.Am2016-2824  0.45
2015 Roberts PJ, White HS, Sorrentino JA, Tadema H, Sale M, Tiessen RG, Bisi JE, Makhuli KM, Hoogdalem Ev, Malik RK, Strum JC. Evaluation of targeted bone marrow arrest by G1T28, a CDK4/6 inhibitor in clinical development to reduce chemotherapy-induced myelosuppression. Journal of Clinical Oncology. 33: 2529-2529. DOI: 10.1200/Jco.2015.33.15_Suppl.2529  0.356
2015 Tiessen RG, Roberts PJ, Sorrentino JA, White HS, Makhuli KM, Bisi JE, Strum JC, Hoogdalem Ev, Malik RK. First-in-human Phase 1 safety, PK, and PD study of the CDK4/6 inhibitor G1T28. Journal of Clinical Oncology. 33: 2527-2527. DOI: 10.1200/Jco.2015.33.15_Suppl.2527  0.43
2015 Sorrentino JA, He S, Bisi JE, Roberts PJ, Strum JC, Sharpless NE. Abstract 941: G1T28-1, a novel CDK4/6 inhibitor, protects murine hematopoietic stem and progenitor cells from cytotoxic chemotherapy Cancer Research. 75: 941-941. DOI: 10.1158/1538-7445.Am2015-941  0.654
2015 Bisi JE, White HS, Sorrentino JA, Roberts PJ, Strum JC. Abstract 1784: Pre-clinical characterization of G1T28-1, a novel CDK 4/6 inhibitor for protection of bone marrow from cytotoxic chemotherapies Cancer Research. 75: 1784-1784. DOI: 10.1158/1538-7445.Am2015-1784  0.446
2014 Sorrentino JA, Sanoff HK, Sharpless NE. Defining the toxicology of aging. Trends in Molecular Medicine. 20: 375-84. PMID 24880613 DOI: 10.1016/J.Molmed.2014.04.004  0.508
2014 Sanoff HK, Deal AM, Krishnamurthy J, Torrice C, Dillon P, Sorrentino J, Ibrahim JG, Jolly TA, Williams G, Carey LA, Drobish A, Gordon BB, Alston S, Hurria A, Kleinhans K, et al. Effect of cytotoxic chemotherapy on markers of molecular age in patients with breast cancer. Journal of the National Cancer Institute. 106: dju057. PMID 24681605 DOI: 10.1093/Jnci/Dju057  0.556
2014 Sorrentino JA, Krishnamurthy J, Tilley S, Alb JG, Burd CE, Sharpless NE. p16INK4a reporter mice reveal age-promoting effects of environmental toxicants. The Journal of Clinical Investigation. 124: 169-73. PMID 24334456 DOI: 10.1172/Jci70960  0.519
2013 Burd CE, Sorrentino JA, Clark KS, Darr DB, Krishnamurthy J, Deal AM, Bardeesy N, Castrillon DH, Beach DH, Sharpless NE. Monitoring tumorigenesis and senescence in vivo with a p16(INK4a)-luciferase model. Cell. 152: 340-51. PMID 23332765 DOI: 10.1016/J.Cell.2012.12.010  0.552
2013 Jeck WR, Sorrentino JA, Wang K, Slevin MK, Burd CE, Liu J, Marzluff WF, Sharpless NE. Circular RNAs are abundant, conserved, and associated with ALU repeats Rna. 19: 141-157. PMID 23249747 DOI: 10.1261/Rna.035667.112  0.614
2012 Liu W, Monahan KB, Pfefferle AD, Shimamura T, Sorrentino J, Chan KT, Roadcap DW, Ollila DW, Thomas NE, Castrillon DH, Miller CR, Perou CM, Wong KK, Bear JE, Sharpless NE. LKB1/STK11 inactivation leads to expansion of a prometastatic tumor subpopulation in melanoma. Cancer Cell. 21: 751-64. PMID 22698401 DOI: 10.1016/J.Ccr.2012.03.048  0.612
Show low-probability matches.